South Korean Samsung Biologics announced this Monday the acquisition of its first drug production unit in the United States, belonging to GSK, for $280 million.
The company’s U.S. unit, Samsung Biologics America, will acquire 100% of Rockville, Maryland-based Human Genome Sciences, the South Korean contract drug maker said in a statement.
Samsung Biologics plans additional investments to increase the capacity of the unit, currently 60,000 liters of raw material, and to upgrade the technology, he said.
He also added that the value of the acquisition could change once the transaction is finalized, likely around the end of the first quarter of 2026.
South Korea’s Celltrion also plans to produce drugs in the United States, where the government has threatened to impose tariffs on pharmaceuticals.
Under a deal with the United States, tariffs on U.S. imports of South Korean pharmaceuticals will not exceed 15 percent, while generic drugs will be exempt from tariffs.
Shares of Samsung Biologics fell 0.4% on Monday, below the broader market’s 2% rise.
About The Author
